The National Institute for Health and Care Excellence (NICE) has approved the combination of , an , plus , a tyrosine kinase inhibitor, for the of people with advanced on the NHS in England and Wales.
The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which the combination showed significant improvement in survival andto treatment compared to the standard of care with .
plus reduced the risk of the getting worse by 61% and the time to when the started growing again and the treatment stopped working ( -free survival) was 2 years compared to 9.2 months for .
The combination reduced the risk of death by 34% versus. 71% of patients responded to treatment and their reduced in size versus 36% with . 16% of people had a and 55% had a to treatment with plus compared to 4% and 32% for those on .
can cause immune-related , which may be severe or fatal and can affect any organ or tissue in the body. However, if identified early they can be managed to ensure the safe use of .